Table 2.
Cancer characteristics
| Invasive carcinoma (n = 124) | DCIS (n = 18) | ||
|---|---|---|---|
| Lesion type | |||
| Mass | 91 (73) | 5 (28) | |
| Non-mass enhancement | 31 (25) | 13 (72) | |
| Focus | 2 (2) | 0 (0) | |
| Lesion size | |||
| Median | 19.5 mm | 13.5 mm | |
| 1st quartile, 3rd quartile | 13 mm, 32.3 mm | 9.3 mm, 19.5 mm | |
| Tumor grade of DCIS | |||
| Microinvasive carcinoma | NA | 3 (17) | |
| High grade DCIS | NA | 4 (22) | |
| Intermediate grade DCIS | NA | 10 (56) | |
| Low grade DCIS | NA | 1 (6) | |
| Tumor grade of invasive carcinoma* | |||
| Grade 1 (well differentiated) | 7 (6) | NA | |
| Grade 2 (moderately differentiated) | 48 (39) | NA | |
| Grade 3 (poorly differentiated) | 56 (45) | NA | |
| Not available | 13 (10) | NA | |
| Histopathology* | |||
| Invasive ductal carcinoma | 98 (79) | NA | |
| Invasive lobular carcinoma | 20 (16) | NA | |
| Mixed invasive ductal/lobular carcinoma | 6 (5) | NA | |
| Molecular subtype* | |||
| Triple negative type | (HR−, HER2−) | 12 (10) | NA |
| HER2 type (HR−) | (HR−, HER2+) | 5 (4) | NA |
| HER2 type (HR+) | (HR+, HER2+) | 16 (13) | NA |
| Luminal type | (HR+, HER2−) | 91 (73) | NA |
| Lymph node metastasis status* | |||
| Positive | 57 (46) | NA | |
| Negative | 64 (52) | NA | |
| Not available | 3 (2) | NA | |
| Oncotype DX recurrence score† | |||
| High risk | 2 (4) | NA | |
| Intermediate risk | 13 (29) | NA | |
| Low risk | 30 (67) | NA | |
*Data for invasive carcinomas
†Data for 45 invasive carcinomas for which Oncotype DX score was available
DCIS ductal carcinoma in situ, NA not applicable